History

Founded in July 2014 by a team of stem cell researchers and biotech business partners, Taiwan Bio Therapeutics has since been devoted to the development of human mesenchymal stem cell products utilizing a proprietary cell expansion technology transferred from National Yang-Ming University and Veterans General Hospital in Taipei. This technology platform can significantly increase the efficiency of cell expansion and postpone cell ageing during culture, and increase the engraftment rate of MSCs after transplantation. This outstanding technology was both the winner of 2015 Taipei Biotech Innovation of the Year Award to the Biothech Industry, and the BioTaiwan 2015 Technology Transfer Cooperation Award.

Taiwan Bio owns a proprietary cell expansion technology of manufacturing human mesenchymal stem cell into novel therapeutic products through the cells’ capability of self-renewal and differentiation into tissues when transplanted to patients. Two of the MSC products have been in the process of either preclinical or clinical study: Biochymal® is developed for the treatment of critical limb ischemia and Chondrochymal® will be applied to the treatment of knee osteoarthritis. More mesenchymal stem cell-related or derived products and/or more diverse indications will be continuously under clinical development for allogenic use.

Mission Statement

To provide human mesenchymal stem cell therapeutic products for use in regeneration medicine, utilizing our novel patented cell expansion technology.

Our Vision

Through the use of our proprietary cell expansion technology, to offer more diverse and better cell or cell-derived products to patients in need through the clinical research and development of MSC therapy in different indications, including cardiovascular diseases, osteoarthritis, immune disorders and cancer.

Business Operation

1. Sponsoring clinic trials conducted at Taipei Veterans General Hospital to establish the core value of our proprietary MSC production technology.

The initial focus of our business investment is on the development of early-phase clinical trials for the application of MSCs. After successful completion of early-phase clinical trials conducted at the prestigious Taipei VGH through the coordination from qualified CRO, we will seek out international cooperation with global firms for later phases of product development. The further licensing-out of our patent will bring in additional funding sufficient for completion of product commercialization. Such strategy will also help to reduce the risk of independent business investment on new drug development.

2. Product development of biological derivatives from manufacturing of MSC for application in aesthetic medicine, and manufacturing of stem cell products or derivatives to the requested specifications for other potential business customers.